entertainment -WSS

entertainment

author：comprehensive 2025-08-11 02:16:03 - browse：9397

Insitro CEO and founder Daphne Koller Neilson Barnard/Getty Images for The New York Times

SAN FRANCISCO — It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.

Koller’s company, Insitro, in a matter of months raised over $100 million from big-name investors including ARCH, Foresite Capital, Andreessen Horowitz, and the firm that manages Jeff Bezos’ personal VC investments. (Koller refers to Bezos by his first name.) Now, it’s time for the next step. On Tuesday, the giant drug maker Gilead Sciences said it would pay Insitro $15 million — and up to $1 billion more down the line if it meets certain goals — for help in developing drugs to treat a common liver disease. It is the South San Francisco-based company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

The very nature of the financials emphasize the exciting but risky reality: The technology has great promise, but nothing is guaranteed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： U.K. sequencing study surfaces new findings about tumor DNA

hotspot

explore

WSS

3 trends to watch in health tech's hiring outlook for 2024

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Morgan Health, with ambitious aims, wants you to know it’s still here

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Goldman Sachs launches $650M fund for life science investments

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

leisure time

entertainment

knowledge

Jerome Adams on the need for new antivirals for Covid

White House finalizes ITC's import ban of latest Apple Watches

Wildfire smoke exposes gaps in outdoor worker protections

Federal weight loss drug coverage is 30 years out of date

Hepatitis C has a cure — but many Americans still lack access to it

White House finalizes ITC's import ban of latest Apple Watches

At least 13 dead in Texas as scorching temps continue

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Supreme Court strikes down use of affirmative action

The biotech scorecard for Q1: 17 stock

leisure time

Antibiotic resistance and the global rise in human conflict

Feng Zhang CRISPR delivery startup lays off quarter of staff

The FDA must approve intranasal treatments for anaphylaxis

Goldman Sachs launches $650M fund for life science investments

Community Health Systems hospitals under DOJ investigation

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

explore

hotspot

explore

Wikipedia